Epic Sciences Announces Completion of New York State Licensure to Provide the Oncotype DX AR-V7 Nucleus Detect Test for Patients with Metastatic Castration-Resistant Prostate Cancer in New York State

Wednesday, March 20, 2019 Press Release
Email Print This Page Comment bookmark
Font : A-A+

SAN DIEGO, March 20, 2019 /PRNewswire/ -- Epic Sciences, Inc. (Epic) announced today that the New

York State Department of Health has completed licensure to provide the Oncotype DX® AR-V7 Nucleus Detect™ test for patients with metastatic castration-resistant prostate cancer (mCRPC). The Oncotype DX AR-V7 Nucleus Detect test helps
determine which patients may benefit from androgen receptor signaling inhibitor (ARSi) therapy and which may benefit from chemotherapy. The Oncotype DX AR-V7 Nucleus Detect test is a circulating tumor cell (CTC)-based, liquid biopsy test that is commercially available in the United States through Epic's partnership with Genomic Health. 

"The Oncotype DX AR-V7 Nucleus Detect test is the first and only liquid biopsy test of its kind that can help doctors prolong the lives of men diagnosed with metastatic castration-resistant prostate cancer. We achieved this important regulatory milestone and met the state department of health's very high standards by demonstrating the test's excellent accuracy and ability to extend lives. Patients and physicians in New York can now access this powerful information to guide therapy decisions," said Pascal Bamford, Ph.D., Chief Scientific Officer and Head of Laboratory Operations.

To obtain this licensure to serve the approximately 5,000 men in New York with advanced prostate cancer, Epic Sciences submitted to NYSDOH a robust dossier of data published in JAMA Oncology establishing the predictive benefit of the test, in addition to analytical performance data demonstrating the quality of the test.

In October, Palmetto GBA issued a positive final Local Coverage Determination to provide coverage for the Oncotype DX AR-V7 Nucleus Detect test, effective December 10, 2018. The test is now covered by Medicare in the U.S. for qualified patients, giving them the opportunity to personalize their cancer treatment.

About Epic Sciences Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences' mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences No Cell Left Behind® technology helps match patients to therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX AR-V7 Nucleus Detect test, which helps with therapeutic decisions between taxane chemotherapy or androgen-directed therapeutics in metastatic castrate-resistant prostate cancer. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences' goal is to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices. Epic Sciences is headquartered in San Diego. Further information is available on the Company's website, www.epicsciences.com. Stay in touch on LinkedIn or on Twitter @EpicSciences.

Media Contacts:

Jennifer GuzmanEpic Sciences858-216-2217 jennifer.guzman@epicsciences.com

Cammy DuongCanale Communications619-849-5389 cammy@canalecomm.com 

 

Cision View original content:http://www.prnewswire.com/news-releases/epic-sciences-announces-completion-of-new-york-state-licensure-to-provide-the-oncotype-dx-ar-v7-nucleus-detect-test-for-patients-with-metastatic-castration-resistant-prostate-cancer-in-new-york-state-300815389.html

SOURCE Epic Sciences, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store